NEXGEL Finalizes Celularity Acquisition with $11.9M Strategic Financing, Expects Triple Revenue

summarizeSummary

NEXGEL, Inc. completed its acquisition of Celularity's degenerative disease segment, securing $11.9 million in convertible notes and warrants, a move expected to triple annual revenue to $35 million and achieve immediate profitability.

check_boxKey Events

• Acquisition Completed

  NEXGEL finalized the acquisition of Celularity Inc.'s degenerative disease segment on April 17, 2026, establishing a new BioNX Surgical division. This follows the initial agreement disclosed in a March 10, 2026 8-K filing.

• Strategic Financing Secured

  The company raised $11.9 million through a private placement of convertible promissory notes and warrants. This includes a $5.0 million convertible note issued to Celularity and $6.9 million from accredited investors, with commitments for an additional $475,000.

• Significant Revenue Growth Expected

  The acquisition is projected to approximately triple NEXGEL's annual revenue to $35 million on a pro-forma basis and is anticipated to be immediately accretive to profitability, addressing the company's prior 'going concern' warning.

• Dilutive Capital Structure

  The convertible notes have an initial conversion price of $0.60 per share, a discount to the current market price, and warrants are exercisable at $0.80 per share. The aggregate number of shares issuable is subject to a 19.99% cap unless shareholder approval is obtained, which the company has agreed to seek within 60 days.

auto_awesomeAnalysis

This 8-K details the completion of NEXGEL's previously announced acquisition of Celularity's degenerative disease segment, a strategic move expected to significantly transform the company's financial profile. The acquisition is being financed by a substantial $11.9 million capital raise through convertible notes and warrants, which is critical given the company's prior 'going concern' warning. While the financing involves significant potential dilution, with notes convertible at a discount to the current stock price, it provides essential capital for growth and is projected to triple NEXGEL's annual revenue to approximately $35 million and make the company immediately profitable. This transaction, supported by a new strategic partner, addresses immediate financial stability concerns and positions NEXGEL for accelerated commercial expansion in regenerative medicine.